Lees-Rolfe Garth
Insider CIK 2017374 · IKT Chief Financial Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| IKT Inhibikase Therapeutics, I | A Award deriv | 2025-01-21 | 2025-01-22 | 90,000 | — | $0 | 90,000 | SEC↗ |
| IKT Inhibikase Therapeutics, I | D To issuer deriv | 2025-01-21 | 2025-01-22 | 90,000 | — | $0 | 0 | SEC↗ |
| IKT Inhibikase Therapeutics, I | A Award deriv | 2025-01-21 | 2025-01-22 | 5,834 | — | $0 | 5,834 | SEC↗ |
| IKT Inhibikase Therapeutics, I | D To issuer deriv | 2025-01-21 | 2025-01-22 | 5,834 | — | $0 | 0 | SEC↗ |
| IKT Inhibikase Therapeutics, I | A Award deriv | 2025-01-03 | 2025-01-07 | 235,383 | — | $0 | 235,383 | SEC↗ |
| IKT Inhibikase Therapeutics, I | A Award deriv | 2025-01-03 | 2025-01-07 | 470,861 | — | $0 | 470,861 | SEC↗ |
| IKT Inhibikase Therapeutics, I | A Award deriv | 2025-01-03 | 2025-01-07 | 432,853 | — | $0 | 432,853 | SEC↗ |
| IKT Inhibikase Therapeutics, I | A Award deriv | 2024-04-01 | 2024-04-02 | 90,000 | — | $0 | 90,000 | SEC↗ |